Christopher Longshaw

3.2k total citations
56 papers, 1.9k citations indexed

About

Christopher Longshaw is a scholar working on Molecular Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Christopher Longshaw has authored 56 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Medicine, 23 papers in Pharmacology and 19 papers in Epidemiology. Recurrent topics in Christopher Longshaw's work include Antibiotic Resistance in Bacteria (25 papers), Antibiotics Pharmacokinetics and Efficacy (23 papers) and Antibiotic Use and Resistance (19 papers). Christopher Longshaw is often cited by papers focused on Antibiotic Resistance in Bacteria (25 papers), Antibiotics Pharmacokinetics and Efficacy (23 papers) and Antibiotic Use and Resistance (19 papers). Christopher Longshaw collaborates with scholars based in United Kingdom, Japan and United States. Christopher Longshaw's co-authors include Mark H. Wilcox, Scott Nicholson, Jane Freeman, Jon J. Vernon, K. Morris, Davide Manissero, S. L. Todhunter, Yoshinori Yamano, Anne Santerre Henriksen and Helen Ashwin and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and CHEST Journal.

In The Last Decade

Christopher Longshaw

54 papers receiving 1.8k citations

Peers

Countries citing papers authored by Christopher Longshaw

Since Specialization

Citations

This map shows the geographic impact of Christopher Longshaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Longshaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Longshaw more than expected).

Fields of papers citing papers by Christopher Longshaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Longshaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Longshaw. The network helps show where Christopher Longshaw may publish in the future.

Co-authorship network of co-authors of Christopher Longshaw

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Longshaw. A scholar is included among the top collaborators of Christopher Longshaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Longshaw. Christopher Longshaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 2025 ·Journal of Antimicrobial Chemotherapy ·Rosy Reynolds, Shazad Mushtaq, Russell Hope, Carolyne Horner, (unknown), (unknown), Olisaeloka Nsonwu, (unknown), Christopher Longshaw, Benjamin J. Parcell, David M. Livermore	1
2	P-1475. Real-World Effectiveness and Safety of Cefiderocol in the Treatment of Patients with Serious Gram-negative Bacterial Infections: Results of the PROVE Chart Review Study 2025 ·Open Forum Infectious Diseases ·Cornelius J. Clancy, (unknown), (unknown), Sean Nguyen, (unknown), (unknown), Christopher Longshaw, Stephen Marcella, (unknown)	1
3	Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019 2025 ·Journal of Antimicrobial Chemotherapy ·Rosy Reynolds, D. Felmingham, Shazad Mushtaq, Carolyne Horner, (unknown), (unknown), (unknown), Christopher Longshaw, Benjamin J. Parcell, David M. Livermore	1
4	The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations 2025 ·Journal of Antimicrobial Chemotherapy ·(unknown), Rosy Reynolds, Shazad Mushtaq, Olisaeloka Nsonwu, Russell Hope, Carolyne Horner, Christopher Longshaw, Benjamin J. Parcell, David M. Livermore	5
5	Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019) 2025 ·Journal of Antimicrobial Chemotherapy ·Carolyne Horner, Rosy Reynolds, Shazad Mushtaq, (unknown), (unknown), (unknown), Christopher Longshaw, Benjamin J. Parcell, David M. Livermore	1
6	Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy 2024 ·Antimicrobial Resistance and Infection Control ·Matteo Bassetti, Gianpaola Monti, Anne Santerre Henriksen, Christopher Longshaw	3
7	In vivoefficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versusAcinetobacter baumannii 2023 ·Journal of Antimicrobial Chemotherapy ·Christian M Gill, (unknown), Miki Takemura, Christopher Longshaw, Yoshinori Yamano, Roger Echols, David P. Nicolau	20
8	Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing 2022 ·Journal of Antimicrobial Chemotherapy ·Erika Matuschek, Christopher Longshaw, Miki Takemura, Yoshinori Yamano, Gunnar Kahlmeter	45
9	Epidemiology, Outcomes and Resource Utilisation in Patients with Carbapenem Non-susceptible Gram-Negative Bacteria in the UK: A Retrospective, Observational Study (CARBAR UK) 2022 ·Advances in Therapy ·Simon Goldenberg, Andrew Dodgson, Gavin Barlow, Benjamin J. Parcell, Lim Jones, Mahableshwar Albur, A.P.R. Wilson, David Enoch, (unknown), Christianne Micallef, Davide Manissero, Christopher Longshaw, Sara Lopes, (unknown)	6
10	In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018 2021 ·Journal of Global Antimicrobial Resistance ·Vanya Gant, Abid Hussain, (unknown), Christopher Longshaw, Anne Santerre Henriksen	11
11	In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany 2021 ·Journal of Global Antimicrobial Resistance ·(unknown), Anne Santerre Henriksen, Christopher Longshaw, Yoshinori Yamano, (unknown), Axel Hamprecht	4
12	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins 2021 ·Clinical Microbiology and Infection ·Florian Wagenlehner, Ersilia Lucenteforte, Federico Pea, Àlex Soriano, Lara Tavoschi, Victoria Steele, Anne Santerre Henriksen, Christopher Longshaw, Davide Manissero, (unknown), Jason M. Pogue	104
13	In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014−2018 studies in Spain 2021 ·Journal of Global Antimicrobial Resistance ·Emilia Cercenado, Laura Cardeñoso, (unknown), Christopher Longshaw, Anne Santerre Henriksen, Álvaro Pascual	17
14	1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol 2020 ·Open Forum Infectious Diseases ·Yoshinori Yamano, Miki Takemura, Christopher Longshaw, Roger Echols	7
15	Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial 2017 ·The Lancet Infectious Diseases ·Benoît Guéry, Francesco Menichetti, Veli-Jukka Anttila, (unknown), José María Aguado, Karen Bisnauthsing, (unknown), Simon Goldenberg, Andreas Karas, Gbenga Kazeem, Christopher Longshaw, José Palacios, Oliver A. Cornely, Maria J. G. T. Vehreschild	143
16	Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production 2016 ·PLoS ONE ·C. H. Chilton, G. S. Crowther, Helen Ashwin, Christopher Longshaw, Mark H. Wilcox	27
17	Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013 2016 ·Eurosurveillance ·Kerrie Davies, Helen Ashwin, Christopher Longshaw, D.A. BURNS, Georgina Davis, Mark H. Wilcox, (unknown)	144
18	Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes 2014 ·Clinical Microbiology and Infection ·Jane Freeman, Jon J. Vernon, K. Morris, Scott Nicholson, S. L. Todhunter, Christopher Longshaw, Mark H. Wilcox	217
19	Is the GehD Lipase from Staphylococcus epidermidis a Collagen Binding Adhesin? 2002 ·Journal of Biological Chemistry ·M. Gabriela Bowden, Livia Visai, Christopher Longshaw, Keith T. Holland, Pietro Speziale, Magnus Höök	80
20	Ventriculoperitoneal shunt infection caused by Staphylococcus lugdunensis 2001 ·Clinical Microbiology and Infection ·Jonathan Sandoe, Christopher Longshaw	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact